CTRI/2021/07/034670尚未招募未知
Development of an ex-vivo assay of SARS COV-2 specific T-cell responses using an interferon gamma assay
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Above 18 years of age
- •2.Recent SARS COV-2 infection (recovered or active) detected by rapid antigen test or real time reverse transcription-polymerase chain reaction (RT-PCR) test for COVID-19
- •3.Primary contact of a SARS COV-2 patient diagnosed as above
- •4.Patient or their surrogate is willing and able to provide written informed consent and comply with all protocol requirements
排除标准
- •1. Below 18 years of age
- •2. Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses
- •3. Obstructive pneumonia induced by lung cancer or other known causes
- •4. Significant comorbid illness likely to impact the outcome of COVID-19 including but not limited to active malignancy other than skin cancer.
- •5. History of long-term use of immunosuppressive agents including prednisone dose >5mg daily over the 30 days prior to enrollment.
- •6. History of severe chronic respiratory disease and requirement for long-term oxygen therapy
- •7. Undergoing hemodialysis or peritoneal dialysis
- •8. Estimated or actual rate of creatinine clearance < 15 ml/min
- •9. History of moderate and severe liver disease (Child-Pugh score >12)
- •10. History of substance abuse sufficient that the patient is unlikely to comply with testing requirements.
- •11. History of deep venous thrombosis, pulmonary embolism, cerebral vascular disease within the last 3 years
- •12. Known HIV, hepatitis virus, or syphilis infection
- •13. Co-Infection of tuberculosis, influenza virus, adenovirus and other respiratory infection virus
- •14. Moribund patient not expected to survive > 24hours
- •15. Any condition unsuitable for the study as determined by the investigators
- •16. Female subjects with a positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period.
- •17. Receipt of experimental therapy for COVID-19 with the exception of convalescent plasma, dexamethasone or another corticosteroid, or remdesivir in an open label study.
- •18. Previous or ongoing immune deficient states â?? active malignancy , undergoing chemotherapy or radiotherapy, active secondary sepsis, post-transplant , patients with immunological/ rheumatologic disorders, active HIV infection
研究者
相似试验
已完成
不适用
Validation of new detection methods for SARS CoV-2 in suspected COVID-19SARS CoV-2U07.1COVID-19, virus identifiedDRKS00021578niversität KonstanzLehrstuhl Zellbiologie280
尚未招募
不适用
A study to identify SARS-CoV-2 in Red Blood Cells in infected patients.CTRI/2021/01/030630All India Institute of Medical Sciences
进行中（未招募）
1 期
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study - The CoVVacBoost StudyCovid (Coronavirus disease)- 19 immunisationMedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-006172-16-ATMedical University of Graz1,200
已完成
不适用
Establishment of COVID-19 diagnostic method by new PCR device using a small amount of saliva as a sampleCOVID-19JPRN-UMIN000044435Tsurumi University20
尚未招募
不适用
Determination of the SARS-CoV-2/COVID-19 seroprevalence of patients in emergency rooms at the university hospitals in North Rhine-WestphaliaSeroprevalence of SARS-CoV-2 antibodies in emergency room patientsDRKS00029414Institut für Virologie Uniklinik Köln3,000